227 related articles for article (PubMed ID: 30361080)
1. Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial.
Cheong PK; Ford AC; Cheung CKY; Ching JYL; Chan Y; Sung JJY; Chan FKL; Wu JCY
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):837-844. PubMed ID: 30361080
[TBL] [Abstract][Full Text] [Related]
2. Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study.
Agger JL; Schröder A; Gormsen LK; Jensen JS; Jensen TS; Fink PK
Lancet Psychiatry; 2017 May; 4(5):378-388. PubMed ID: 28408193
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial.
Wauters L; Slaets H; De Paepe K; Ceulemans M; Wetzels S; Geboers K; Toth J; Thys W; Dybajlo R; Walgraeve D; Biessen E; Verbeke K; Tack J; Van de Wiele T; Hellings N; Vanuytsel T
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):784-792. PubMed ID: 34358486
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
5. Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan.
Iwakiri R; Tominaga K; Furuta K; Inamori M; Furuta T; Masuyama H; Kanke K; Nagahara A; Haruma K; Kinoshita Y; Higuchi K; Takahashi S; Kusano M; Iwakiri K; Kato M; Hongo M; Hiraishi H; Watanabe S; Miwa H; Naito Y; Fujimoto K; Arakawa T
Aliment Pharmacol Ther; 2013 Oct; 38(7):729-40. PubMed ID: 23957383
[TBL] [Abstract][Full Text] [Related]
6. Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn: A Randomized Placebo-Controlled Trial.
Limsrivilai J; Charatcharoenwitthaya P; Pausawasdi N; Leelakusolvong S
Am J Gastroenterol; 2016 Feb; 111(2):217-24. PubMed ID: 26753892
[TBL] [Abstract][Full Text] [Related]
7. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial.
Talley NJ; Verlinden M; Snape W; Beker JA; Ducrotte P; Dettmer A; Brinkhoff H; Eaker E; Ohning G; Miner PB; Mathias JR; Fumagalli I; Staessen D; Mack RJ
Aliment Pharmacol Ther; 2000 Dec; 14(12):1653-61. PubMed ID: 11121915
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study.
Ang TL; Fock KM; Teo EK; Chan YH; Ng TM; Chua TS; Tan JY
J Gastroenterol; 2006 Jul; 41(7):647-53. PubMed ID: 16933001
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nortriptyline in functional dyspepsia in Asians: A randomized double-blind placebo-controlled trial.
Kaosombatwattana U; Pongprasobchai S; Limsrivilai J; Maneerattanaporn M; Leelakusolvong S; Tanwandee T
J Gastroenterol Hepatol; 2018 Feb; 33(2):411-417. PubMed ID: 28768370
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial.
Fukudo S; Endo Y; Hongo M; Nakajima A; Abe T; Kobayashi H; Nakata T; Nakajima T; Sameshima K; Kaku K;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):603-613. PubMed ID: 30056028
[TBL] [Abstract][Full Text] [Related]
12. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
[TBL] [Abstract][Full Text] [Related]
13. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.
van Marrewijk CJ; Mujakovic S; Fransen GA; Numans ME; de Wit NJ; Muris JW; van Oijen MG; Jansen JB; Grobbee DE; Knottnerus JA; Laheij RJ
Lancet; 2009 Jan; 373(9659):215-25. PubMed ID: 19150702
[TBL] [Abstract][Full Text] [Related]
14. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials.
Talley NJ; Tack J; Ptak T; Gupta R; Giguère M
Gut; 2008 Jun; 57(6):740-6. PubMed ID: 17965059
[TBL] [Abstract][Full Text] [Related]
15. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.
Talley NJ; Van Zanten SV; Saez LR; Dukes G; Perschy T; Heath M; Kleoudis C; Mangel AW
Aliment Pharmacol Ther; 2001 Apr; 15(4):525-37. PubMed ID: 11284782
[TBL] [Abstract][Full Text] [Related]
16. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
[TBL] [Abstract][Full Text] [Related]
17. Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Taha AS; McCloskey C; McSkimming P; McConnachie A
Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):469-476. PubMed ID: 29754836
[TBL] [Abstract][Full Text] [Related]
18. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
20. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.
Goudie AR; Lipworth BJ; Hopkinson PJ; Wei L; Struthers AD
Lancet Respir Med; 2014 Apr; 2(4):293-300. PubMed ID: 24717626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
